[To learn English] Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that seeks to challenge Merck's best-selling Keytruda. BioNTech, Pfizer's partner on COVID-19 vaccines, said it was projecting full-year revenue of 2.6 billion euros ($3.03 billion) to 2.8 billion euros, up from a previous guidance range of 1.7 billion to 2.2 billion euros. 德国生物科技公司BioNTech周一上调了其2025年营收预期，此前该公司已收到其新合作伙伴百时美施贵宝（Bristol Myers Squibb）支付的首笔款项。双方在癌症免疫疗法联盟中达成合作，旨在挑战默克公司畅销药Keytruda的地位。 BioNTech是辉瑞公司新冠疫苗的合作伙伴，该公司表示，预计全年营收为26亿至28亿欧元（约合30.3亿美元），高于此前17亿至22亿欧元的预期。 LearnEnglishLeave a remark
